<div><div><h2>Buy Sun Pharma; target of Rs 670: HDFC Securities</h2></div><div>"hdfc securities' research report on sun pharmawith the provision for modafinil litigation liability to the tune of rs 12bn sun pharma (sunp) reported a loss of rs 2.2bn in 2qfy19. however adjusted pat at rs 9.96bn was still 8% below our estimates due to a similar miss on top line. the inventory correction exercise resulted into a 16% fall in india revenues along with slower than expected growth in the us (up 21%yoy) which led to 4%yoy revenue growth in 2qfy19 (8% miss). however ebitda margin remained flat qoq at 22.1% as better product mix and favorable currency boosted gross margin to 74% despite a spike in other expenses on account of the specialty business.outlookat cmp the stock is trading at 33.6x fy19e and 25.4x fy20e eps a ~15% premium to peers. with a significant part of revenues expected to come in from the branded business in 3-4 years we believe the stock is likely to continue trading at a premium. an 8% miss on top line has led us to cut our estimates by ~3% for fy19-20e. maintain buy rating with a tp of rs 670 (25x sep 20e + rs 40/sh option value for specialty).for all recommendations report click heredisclaimer: the views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own and not that of the website or its management. moneycontrol.com advises users to check with certified experts before taking any investment decisions.sun pharma_161118"</div></div>